ProSavin

BIOLOGICAL2 trials

Sponsors

Oxford BioMedica, Axovant Sciences Ltd.

Conditions

Parkinson's Disease

Phase 1

Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease

CompletedNCT00627588

Oxford BioMedicaParkinson's Disease

Start: 2008-01-31End: 2012-08-31Updated: 2013-05-13

Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease

TerminatedNCT01856439

Axovant Sciences Ltd.Parkinson's Disease

Start: 2011-05-31End: 2022-04-30Updated: 2022-05-03

Related Papers

Parkinson's disease gene therapy: a comparative effectiveness review of completed clinical trials in terms of their possible implementation in treatment

MEDICAL SCIENCE PULSE2023-02-271 citations

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

2014-01-10303 citations